Antoine Mouawad, Sofia Habib, Marc Boutros, Fouad Attieh, Hampig Raphaël Kourie
{"title":"如何大海捞针：针对 KRAS 野生型胰腺癌的系统综述。","authors":"Antoine Mouawad, Sofia Habib, Marc Boutros, Fouad Attieh, Hampig Raphaël Kourie","doi":"10.1080/14796694.2024.2355078","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> Pancreatic adenocarcinoma is a very aggressive type of cancer, in which targeted therapies have not yet been fully utilized. <i>KRAS</i> wild-type pancreatic adenocarcinoma tumors are associated with different genomic alterations in comparison to <i>KRAS</i> mutated pancreatic adenocarcinoma. <b>Objective:</b> This systematic review aims to provide a one-stop summary of all these alterations, their proposed targeted treatment and their effect on disease progression. <b>Methods:</b> An electronic search strategy was elaborated in the PubMed database between 2020 and January 2024. <b>Results:</b> 21 studies were included, and we found that the most frequent targetable genomic alterations in <i>KRAS</i> wild-type pancreatic adenocarcinoma were <i>BRAF</i>, <i>EGFR</i>, <i>FGFR</i>, <i>MSI-H/dMMR</i>, <i>Her2/ERBB2</i> amplification, <i>BRCA1/2</i> and other HRDs, and gene fusions like <i>ALK</i>, <i>NTRK</i> and <i>NRG1</i>.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-9"},"PeriodicalIF":3.0000,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"How to find a needle in a haystack: a systematic review on targeting KRAS wild-type pancreatic cancer.\",\"authors\":\"Antoine Mouawad, Sofia Habib, Marc Boutros, Fouad Attieh, Hampig Raphaël Kourie\",\"doi\":\"10.1080/14796694.2024.2355078\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> Pancreatic adenocarcinoma is a very aggressive type of cancer, in which targeted therapies have not yet been fully utilized. <i>KRAS</i> wild-type pancreatic adenocarcinoma tumors are associated with different genomic alterations in comparison to <i>KRAS</i> mutated pancreatic adenocarcinoma. <b>Objective:</b> This systematic review aims to provide a one-stop summary of all these alterations, their proposed targeted treatment and their effect on disease progression. <b>Methods:</b> An electronic search strategy was elaborated in the PubMed database between 2020 and January 2024. <b>Results:</b> 21 studies were included, and we found that the most frequent targetable genomic alterations in <i>KRAS</i> wild-type pancreatic adenocarcinoma were <i>BRAF</i>, <i>EGFR</i>, <i>FGFR</i>, <i>MSI-H/dMMR</i>, <i>Her2/ERBB2</i> amplification, <i>BRCA1/2</i> and other HRDs, and gene fusions like <i>ALK</i>, <i>NTRK</i> and <i>NRG1</i>.</p>\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":\" \",\"pages\":\"1-9\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-06-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14796694.2024.2355078\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2355078","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
How to find a needle in a haystack: a systematic review on targeting KRAS wild-type pancreatic cancer.
Aim: Pancreatic adenocarcinoma is a very aggressive type of cancer, in which targeted therapies have not yet been fully utilized. KRAS wild-type pancreatic adenocarcinoma tumors are associated with different genomic alterations in comparison to KRAS mutated pancreatic adenocarcinoma. Objective: This systematic review aims to provide a one-stop summary of all these alterations, their proposed targeted treatment and their effect on disease progression. Methods: An electronic search strategy was elaborated in the PubMed database between 2020 and January 2024. Results: 21 studies were included, and we found that the most frequent targetable genomic alterations in KRAS wild-type pancreatic adenocarcinoma were BRAF, EGFR, FGFR, MSI-H/dMMR, Her2/ERBB2 amplification, BRCA1/2 and other HRDs, and gene fusions like ALK, NTRK and NRG1.
期刊介绍：
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
